Increased screening may better predict those at higher risk for heart disease, research... ( DALLAS May 26 2008 Adding noninvas...)

Increased screening may better predict those at higher risk for heart disease, researchers report

Date:5/26/2008

DALLAS May 26, 2008 Adding noninvasive imaging to current risk-assessment protocols may identify more people who are at risk of developing heart disease, UT Southwestern Medical Center researchers have found.

Researchers used data from the UT Southwestern-led Dallas Heart Study to determine whether using computed tomography (CT) to scan patients hearts for calcium deposits and blockages could identify more people at high risk for heart disease and who could benefit from cholesterol-lowering therapy.

The recommendations by the Screening for Heart Attack Prevention and Education (SHAPE) task force are a proposed update to the current guidelines, were updated by the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) in 2004.

In findings published in todays edition of Archives of Internal Medicine, researchers found that the additional imaging proposed by the SHAPE task force did indeed increase the number of patients classified at high risk.

We added imaging of coronary artery calcium, as recommended by the SHAPE task force, to determine if this strategy would augment current risk assessment, said Dr. Jason Lindsey, an author of the paper and cardiology fellow at UT Southwestern.

The efficiency of calcium screening according to the SHAPE recommendations was determined by the number of people who had to be scanned before a single participant was reclassified as either meeting or not meeting individual cholesterol goals.

In our sample of participants in the Dallas Heart Study, we found that by applying SHAPE recommendations compared with the current guidelines (NCEP-ATP III) there was a 27 percent relative increase in the proportion of patients who would need lipid-lowering therapy, said Dr. James de Lemos, associate professor of internal medicine at UT Southwestern and the studys senior author.

SHAPE calls for a broader application of atherosclerosis imagi
'/>"/>

Contact: Katherine Morales
katherine.morales@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Cumulative radiation exposure shows increased cancer risk for emergency department patients
2. Men at increased risk of death from pneumonia compared to women
3. Somanetics Announces Share Repurchase Program Increased by $15 Million
4. TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity
5. PPO Industry Calls for Increased Collaboration Among Non-Traditional Allies
6. Obese patients face increased risks for infection and dislocation following revision hip surgery
7. Obesity linked to increased risk for dementia
8. Catholic Charities Calls for Increased Support of Mothers in Need:
9. Garmin Reports Record First Quarter; Strong Margins and Increased Market Share
10. Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
11. Low Vitamin D Levels Associated With an Increased Risk of Peripheral Arterial Disease

Post Your Comments:

Related Image:

Increased screening may better predict those at higher risk for heart disease, researchers report

(Date:12/3/2009)...sue of Deutsches rzteblatt International contain...xperience with the novel influenza A virus (H1N1/0...t of the pandemic. Ralf Winzer and his coauthors f...ely evaluated data from a large clinical cohort of...2009; 106[47]: 770-6). Their medical-scientific ar...

(Date:12/3/2009)... 450 Deaths a day is still too many - s...k. , Atlanta, GA, Geneva,...3, 2009 -- The Measles Initiative announced today ...2000 and 2008, from an estimated 733 000 in 2000 t...perts warn of a resurgence in measles deaths if va...

(Date:12/3/2009)... Nutra Pharma will be conducting a webi...squo;s over-the-counter and prescription treatment... Plantation, FL (Vocus) Decem... biotechnology company that is developing treatmen...le Sclerosis (MS), has announced today that it wil...

(Date:12/3/2009)...ANTA ROSA, Calif., Dec. 3 Osseon T...eerable and curvable bone cement delivery needle) ...l) systems for percutaneous vertebral augmentation...alth Canada for marketing and clinical use in Cana... corresponds to FDA approval in the United States,...

(Date:12/3/2009)...AScientists at Boston Biomedical Research Institut...ound that combining two chemicals, one of which is...stroy a variety of protein structures known as amy...brain disorders such as Alzheimer,s, Huntington,s,... in the current issue of Nature Chemical Biology ...

Breaking Medicine News(10 mins):Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 2 Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 3 Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 4 Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 2 Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 3 Health News:Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada 2 Health News:Green tea chemical combined with another may hold promise for treatment of brain disorders 2

[0] The swine flu pandemic [0] Global Measles Deaths Drop By 78%, But Resurgence Likely [0] Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain [0] Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada [0] Green tea chemical combined with another may hold promise for treatment of brain disorders

... Dr. Wayne Andersen to discuss weight management...uot; which is helping thousands maintain permanent...le-Dublin, Ohio (PRWEB) April 30, 2009 -- Dr. Wayn...three free seminars in the Westerville-Dublin area...

... G1G Travel Insurance and Student Funding Group ...l safely; Tuition Fee protection programs also add...se, CA (PRWEB) April 30, 2009 -- With a rise in in...udent Funding Group (StuFund) to offer newly creat...

...and, Ore.) A brief intervention program consisti...ne calls boosted by tenfold the number of women c...the findings of a Kaiser Permanente Center for Hea...intervention programs can be effective in increasi...

...illion in Total Revenues for the Quarter , , SAN ... Realty Trust, Inc. (NYSE: BMR ), a real estate ...to the Life Science Industry(R), today announced o...ter were $94.0 million, up 39.5% from $67.4 millio...

... VA,s Office of Research and Development is at th...eatments based on new knowledge about the role of ... to study genomics--the use of patients, individua...ed network of basic research and clinical applicat...

...ining the mechanism of a novel therapy that uses m... showed the treatment to be a promising alternativ...nial magnetic stimulation, or TMS. Study findings...ntrolled clinical study by Ohio State University M...

Physician and Author to Share Clinically Proven System for Permanent Weight Loss and Optimal Health in Westerville and Dublin, Ohio Areas New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site Women 10 times more likely to do breast self-exams correctly with intervention, KP study finds BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results Video: Turning Hope Into Reality - Genomics Research at the VA New therapy based on magnetic stimulation shows promise for non-drug treatment for migraine

(Date:12/3/2009)...TER, N.Y., Dec. 3 Virtua...er of quantitative imaging for clinical trials, an...ethod for 4D Reconstruction and Visualization" rec...pics, Vice President of Technology and Product Dev...ed that Japan has recognized the uniqueness of Vir...

(Date:12/3/2009)..., ROTTERDAM, The Netherlands, December 3 /PR...ny focused on the discovery and development of hum...y(TM) platform, today,announced the successful sec.... The Company raised an additional EUR 3.0 million...investors, Credit Agricole Private Equity and,VIB ...

(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com...ailable in its catalogue: ,, Cardiac Pacemake...eportlinker.com/p0164335/Cardiac-Pacemakers---A-Wo...constitute a major segment in a rapidly expanding ...ac pacemakers market is characterized by relativel...

[0] VirtualScopics Receives Issuance in Japan of Prominent Patent [0] arGEN-X Concludes EUR 12.5 Million Series A Financing Round [0] Reportlinker Adds Cardiac Pacemakers - A World Market Analysis

...r Similar to Seven-Day in, Achieving Red Blood Cel...t in All MDS Patients Tested...Hematology (ASH) Meeting, ATLANTA, Dec. 11 Pharm...nterim data from a Phase 2 clinical trial,evaluati... Vidaza(R),(azacitidine for injection) that demons...

...city With Equivalent Complete Re...erapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) ann...II/III randomized study comparing CPOP-R to CHOP-R...essive non-Hodgkin,s lymphoma,(NHL) showed patient...(grade 3/4) toxicities including severe infection ...

Other Medicine Technology:MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 2 MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 3 MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 4 MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 5 MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 6 Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2 Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3 Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4 Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5

MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting

Multi Dop T1

EZ-Dop

...owerful automated system capable of handling any c...m 6 user-programmable test protocols to begin a fu...tests not included in the comprehensive list of au...ler, PVR and PPG instrument modes. Provides high f...

CD Horizon M10

Medicine Products:

Multi Dop T1 EZ-Dop Imexlab 9100HS CD Horizon M10

Increased screening may better predict those at higher risk for heart disease, research...( DALLAS May 26 2008 Adding noninvas...),Health